Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy

1 Feb 2022

Abstract excerpt

Pancreatic cancer (PDAC) is a highly aggressive malignancy for which the identification of novel therapies is urgently needed. Here, we establish a human PDAC organoid biobank from 31 genetically distinct lines, covering a representative range of tumor subtypes, and demonstrate that these reflect the molecular and phenotypic heterogeneity of primary PDAC tissue. We use CRISPR-Cas9 genome editing and drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Chromatin Remodeling and Cancer
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35187519
DOI: 10.1016/j.xgen.2022.100095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapyPMID 35187519Read ↗

Integrative genomic identification of therapeutic targets for pancreatic cancerSemantic proximity Read ↗

Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug RepurposingSemantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoidsSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Whole Genomes Define Concordance of Matched Primary, Xenograft, and Organoid Models of Pancreas CancerSemantic proximity Read ↗

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivitySemantic proximity Read ↗

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersSemantic proximity Read ↗

A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapySemantic proximity Read ↗

Clinical study of genomic drivers in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Large-scale multi-omic analysis identifies noncoding somatic driver mutations and nominates<i>ZFP36L2</i>as a driver gene for pancreatic ductal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.